18 July 2007
The London Stock Exchange congratulates Vectura Group plc on its move to the Main Market
Vectura Group plc opened the London markets on Wednesday 18 July, the day the Group completed its move from AIM to the Main Market.
Vectura is a pulmonary drug development company focused principally on the development of a range of inhaled pharmaceuticals for the treatment of respiratory and neurological diseases.
Vectura has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The company also progresses certain programmes to a more advanced stage to optimise their commercial value. In addition, Vectura offers its formulation and inhalation capabilities to other pharmaceutical companies on a licensing basis where this complements Vectura’s business strategy.
Chris Blackwell, Chief Executive of Vectura Group, commented:
“Vectura has made significant advances over the past 12 months and it is an exciting time in the company’s growth strategy. We are delighted to be moving from AIM to the Main Market in London, where we believe we will see additional liquidity and a higher profile with investors.”
In total 315,358,607 ordinary shares of Vectura Group plc have been admitted to the main market today. Vectura Group plc’s advisers were its brokers Piper Jaffray Limited and its solicitors Olswang.